research A functional study of a case of glucagonoma exhibiting typical glucagonoma syndrome
A pancreatic tumor caused high glucagon levels and symptoms, but treatment reduced glucagon and shrank liver tumors.
Search
for
Sort by
Research
390-420 / 1000+ results
research Case Report: Baricitinib improved alopecia areata in a pediatric patient with atopic dermatitis
Baricitinib significantly improved hair regrowth and skin condition in a 14-year-old with alopecia areata and atopic dermatitis.
research Functionally enhanced placenta-derived mesenchymal stem cells inhibit adipogenesis in orbital fibroblasts with Graves’ ophthalmopathy
Enhanced stem cells from the placenta can reduce fat cell formation in eye disease.
research Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A promising therapy for the treatment of alopecia areata: A case report of six patients
Tofacitinib helped regrow hair in patients with alopecia, with few side effects.
research Mechanism of astragaloside A against lung adenocarcinoma based on network pharmacology combined with molecular dynamics simulation technique
Astragaloside A may help fight lung cancer by targeting specific proteins.
research Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO ‐2b/3 and ALLEGRO ‐ LT Clinical Studies for Alopecia Areata
Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.
research Isoallopregnanolone reduces tic‐like behaviours in the D1 CT ‐7 mouse model of Tourette syndrome
Isoallopregnanolone may be a safe and effective treatment for reducing tics in a mouse model of Tourette syndrome.
research Atopic Dermatitis and Multilocular Alopecia Areata Simultaneously Treated With Baricitinib
Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.
research Bioconversion, Pharmacokinetics, and Therapeutic Mechanisms of Ginsenoside Compound K and Its Analogues for Treating Metabolic Diseases
Ginsenoside compound K shows promise for treating metabolic diseases like diabetes and obesity.
research Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis
A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.
research BAYONET trial: staged combination with encorafenib, binimetinib, plus cetuximab following encorafenib plus cetuximab for BRAF V600E-mutant metastatic colorectal cancer
The combination treatment showed a higher response rate but no significant survival benefits.
research Distribution of SALT Scores with Ritlecitinib Treatment up to 24 months from the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata
Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.
research GLP-1 RAs and Skin Health: Exploring Dermatologic Side Effects and Therapeutic Interventions
GLP-1 receptor agonists can cause skin and hair issues due to rapid weight loss, but these can be managed with proper care and treatments.
research Chinese Herbal Medicine, Guilu Erxian Glue, as Alternative Medicine for Adverse Side Effects of Chemotherapy in Doxorubicin-Treated Cell and Mouse Models
Guilu Erxian Glue may help reduce chemotherapy side effects like weight loss and heart stress.
research Improvement of Psoriasis, Psoriatic Arthritis, and Alopecia Universalis during Treatment with Tofacitinib: A Case Report
Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.
research 1329 Transglutaminase 2 deficiency leads to lipid accumulation and reduced autophagy in SZ95 sebocytes
Lack of TG2 increases fat storage and lowers cell cleanup in skin oil cells.
research A Single-Arm, Open-Label, Phase Ib Clinical Study Evaluating the Efficacy and Safety of Durvalumab in Combination with Albumin-Bound Paclitaxel and Carboplatin as Neoadjuvant Therapy for Resectable Stage III Non-Small Cell Lung Cancer
The treatment showed high response rates and was well-tolerated, potentially extending patient survival.
research Drug Repurposing Patent Applications April–June 2021
Drug repurposing shows promise for treating many medical conditions.
research Diguanoside tetraphosphate (Gp₄G) is an epithelial cell and hair growth regulator.
Gp₄G promotes hair growth and improves skin health.
research Alopecia areata: Ritlecitinib generates substantial re-growth of scalp hair
research USE OF TOFACITINIB IN DIFFICULT TO TREAT CLINICALLY AMYOPATHIC DERMATOMYOSITIS
Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.
research Bimatoprost
research Les Rencontres d’Experts du Psoriasis : des recommandations pour la pratique quotidienne
Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.
research Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents
Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
research Inhibitory effects of TripTripterygium wilfordii multiglycoside on benign prostatic hyperplasia in rats
Tripterygium wilfordii multiglycoside effectively reduced prostate enlargement in rats without harmful effects.
research Adverse cutaneous reactions to the new second-generation tyrosine kinase inhibitors (dasatinib, nilotinib) in chronic myeloid leukemia
Many patients on new leukemia drugs had mild to moderate skin reactions.
research Complete Regrowth of Beard Hair with Ruxolitinib in an Alopecia Universalis Patient
Ruxolitinib helped a man regrow his beard after years of hair loss.
research Treatment of alopecia areata with the janus kinase inhibitor upadacitinib: A retrospective cohort study
Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.
research JAK inhibition in the treatment of alopecia areata – a promising new dawn?
JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.
research LB1159 First-in-human clinical trial evaluating AI-09, a novel long-lasting ready-to-use liquid injectable neuromodulator for the treatment of glabellar lines
AI-09 is safe, effective, and reduces wrinkles for up to 6 months.